UCI 趙 Chao Family Comprehensive Cancer Center



Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Open to Accrual | Low Accruing | Pending Activation/Suspended

Colorectal

NEOADJUVANT	ADJUVANT	INTRA-OPERATIVE	MOLECULAR FAILURE
CCTG-CO32 (NEO-RT trial) **(opened 4/29/24)** Coord: P. Yang PI: Dr. Zell Accrual: 3/5		**UCI 24-103** (Y90 Resin Spheres vs SOC of mCRC liver metastases) Coord: TBD PI: Dr. Abi-Jaoudeh Pending activation	**UCI 20-43** (IP + Irinotecan) **(opened 5/24/22)** Coord: A. Ballard PI: Dr. Dayyani Accrual: 14/17

Open to Accrual | Low Accruing | Pending Activation/Suspended

Colorectal

1L METASTATIC

UCI 25-155
(Ivonescimab vs Bev + FOLFOX)

(opened 2/26/26)
Coord: P. Yang
PI: Dr. Dayyani
Accrual 9/15

UCI 25-196
(Pumitamig vs Bev + Chemo)

(opened 4/6/26)
Coord: N. Ferrand
PI: Dr. Dayyani
Accrual 2/5

UCI 26-99
(GCT1158-08)

Coord: TBD

PI: Dr. Dayyani
Pending Activation

2L METASTATIC

ETCTN 10670
(Abemaciclib + 5-Fluorouracil)

(opened 4/8/25)
Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 5/8

ETCTN 10605 (BRAF V600E)
(IP + Cetuximab + Encorafenib)

(opened 1/14/26)
Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 0/3

UCI 25-163
(BBO-11818)

Coord: N. Ferrand
PI: Dr. Arter
Accrual: 0/5

3L METASTATIC

UCI 24-93
(Fruquintinib)

(opened 5/28/25)
Coord: N. Ferrand
PI: Dr. Dayyani
Accrual: 6/14

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 25-149
(Metformin use for Pseudomyxoma Peritonei secondary to appendiceal mucinous neoplasms)
(opened 6/18//26)

Coord: C. Jonsson
PI: Dr. Eng
Accrual: 3/15

Appendix

Open to Accrual Low Accruing Pending Activation/Suspended

Newly Diagnosed

Advanced/Metastatic

Gastric and Gastroesophageal (GEJ)

Open to Accrual | Low Accruing | Pending Activation/Suspended

Neoadjuvant

UCI 21-191
(SOC w/ ctDNA testing)

(opened 6/27/25)
Coord: A. Ballard
PI: Dr. Dayyani
Accrual: 15/30

UCI 23-184
(Pafolacianine for Imaging of Peritoneal Carcinomatosis)

Coord: Y. Kwon
PI: Dr. Senthil
Accrual: 13/20

ESCC

UCI 24-77
(I-DXd)

(opened 2/5/26)
Coord: C. Jonsson
PI: Dr. Dayyani
Accrual: 0/5

Newly Diagnosed Metastatic

A022102
(mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab)

Coord: C. Jonsson
PI: Dr. Dayyani
Accrual: 9/14

UCI 21-10
(FOLFOX + nivo + TJ033721 (anti-CLDN18.2 + anti-4-1BB)

Coord: M. Nguyen; C. Jonsson

PI: Dr. Dayyani
Accrual: 39/50

EA2234
(IP/IV Paclitaxel + 5-FU/LV vs. SOC)

Coord: Y. Kwon
PI: Dr. Senthil
Accrual: 14/65

UCI 26-78
(Sonesitatug Vedotin + Capecitabine +/- Rilvegostomig)
(opened 9/18/26)
Coord: C. Jonsson

PI: Dr. Dayyani
Accrual: 0/10

UCI 25-203
(Pumitamig vs. Nivo + Chemo)

(Phase III opens Dec-2026)
Coord: N. Ferrand
PI: Dr. Dayyani
Accrual: 0/5

UCI 26-127
(ASP2138 + CAPOX/mFOLFOX6 +/- Pembrolizumab)

PI: Dr. Dayyani
Pending activation

Newly Diagnosed Non-Metastatic

UCI 23-173
(Tremelimumab and Durvalumab in ARID1 mutated)
(opened 5/29/26)

PI: Dr. Dayyani
Accrual: 0/34

Recurrent

UCI 16-94
(Tirapazamine + Nivolumab)

Coord: S. Duong
PI: Dr. Abi-Jaoudeh
Accrual: 41/48

UCI 24-49
(Zongertinib + Trastuzumab + Deruxtecan or + Trastuzumab Emtansine)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 3/10

UCI 26-60
(ASP546C)

PI: Dr. Dayyani
Pending activation

Advanced Solid Tumors By Biomarker

Open to Accrual | Low Accruing | Pending Activation/Suspended

HER-2

UCI 24-49
(Zongertinib + Trastuzumab + Deruxtecan or + Trastuzumab Emtansine)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 3/10

KRAS

UCI 25-163
(BBO-11818)

Coord: N. Ferrand

PI: Dr. Arter
Accrual: 0/5

EGFR

CLDN18.2

UCI 21-10
(FOLFOX + nivo + TJ033721 (anti-CLDN 18.2 + anti-4-1BB)

Coord: M. Nguyen/C. Jonsson

PI: Dr. Dayyani
Accrual: 39/50

UCI 26-78
(Sonesitatug Vedotin + Capecitabine +/- Rilvegostomig)
(opened 9/18/26)
Coord: C. Jonsson

PI: Dr. Dayyani
Accrual: 0/10

UCI 26-60
(ASP546C)

Coord: TBD

PI: Dr. Dayyani
Pending activation

Advanced Solid Tumor

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 23-85
(BA3182 + (EPCAM/CD3 AB)

(opened 9/19/24)

Coord: P. Yang
PI: Dr. Valerin
Accrual: 8/18

ETCTN-10572
(Temozolomide + M1774)

(opened 12/11/2025)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 2/10

ETCTN-10579
(ZEN-3694) + capecitabine)

(opened 10/27/23)

Coord: P. Yang
PI: Dr. FC Lee
Accrual: 3/4

UCI 25-181
(TAK-505)

(opened 9/28/26)

Coord: N. Ferrand
PI: Dr. Dayyani
Accrual: 0/20

UCI 24-113
(BMS-986482 +/- immunotherapy)

(opened 9/29/2025)

Coord: L. Mejia
PI: Dr. Chow
Accrual: 5/10

UCI 21-241
(ALK inhibitor NLV-655)

(opened 10/4/22)

Coord: A. Ballard
PI: Dr. Nagasaka
Accrual: 20/25

UCI 25-190 (STOPGAP-B)
(IP Paclitaxel + SOC in GI Malignancies with PC)

(opened 7/31/26)

Coord: Y. Kwon
PI: Dr. Senthil
Accrual: 8/45

ETCTN-10397
(Antibody-Drug Conjugate Therapy)

(opened 10/16/26)
Coord: K. Ghio
PI: Dr. Dayyani
Accrual: 0/5

UCI 25-16
(ODM-212)

(opened 8/29/2025)

Coord: P. Yang
PI: Dr. Dayyani
Accrual: 14/20

UCI 25-75
(CRN09682- on SST2 tumors)

(opened 2/18/2026)

Coord: S. Duong
PI: Dr. Dayyani
Accrual: 0/15

Open to Accrual | Low Accruing | Pending Activation/Suspended

Supportive Trials

UCI 03-03
(Immunologic response analysis)

Coord: B. Sanchez
PI: Dr. Imagawa
Accrual: 336/400

UCI 22-55
(Early Detection and Diagnosis of DNA Repair Deficient Hereditary Cancers)

(opened 3/13/2025)
PI: Dr. Pannunzio/Dr. Valerin
Accrual: 16/50

UCI 24-05
(Riluzole for Cancer- related Cognitive Impairment)

Coord: M. Nguyen
PI: Dr. Chan
Accrual: 34/59

UCI 25-48
(Riluzole For Preventing Cognitive Dysfunction in Pts Receiving Chemo)

Coord: M. Nguyen
PI: Dr. Chan
Accrual: 14/20